Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | C1R | P00736 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5542790 | 0.79 | ELANE (0.56) | ELANEMAPTKMT2AESR1MAPK10 | |
| SCHEMBL25161101 | 0.78 | ELANE (0.39) | ELANEMAPTKMT2AESR1MAPK10 | |
| SCHEMBL2045577 | 0.76 | ALDH1A1 (0.48) | ELANEMAPTKMT2AESR1MAPK10 | |
| SCHEMBL5535332 | 0.76 | PSMB8 (0.56) | ELANEMAPTKMT2AESR1MAPK10 | |
| SCHEMBL25113500 | 0.76 | ELANE (0.47) | ELANEMAPTKMT2AESR1MAPK10 | |
| SCHEMBL17922615 | 0.76 | ELANE (0.47) | ELANEMAPTKMT2AESR1MAPK10 | |
| SCHEMBL1353839 | 0.76 | ELANE (0.50) | ELANEMAPTKMT2AESR1MAPK10 | |
| SCHEMBL5544332 | 0.76 | ELANE (0.47) | ELANEMAPTKMT2AESR1MAPK10 | |
| SCHEMBL1121502 | 0.76 | PSMB8 (0.40) | ELANEKMT2AESR1ALDH1A1MAOA | |
| SCHEMBL2571683 | 0.76 | C1R (0.37) | ELANEKMT2AESR1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055013-B1 | WDR5 INHIBITORS AND MODULATORS | UNIV VANDERBILT (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-111556871-B | 1H-pyrazolo [4,3-b ] pyridines as PDE1 inhibitors | H.隆德贝克有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| US-10889901-B2 | Ultraviolet-stabilized corrosion inhibitors | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2021-01-12 | — | — | US | disclosed |
| US-10766893-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2020-09-08 | — | — | US | disclosed |
| CN-111556871-A | 1H-pyrazolo [4,3-b ] pyridines as PDE1 inhibitors | H.隆德贝克有限公司 | 2020-08-18 | — | — | CN | disclosed |
| US-20200032401-A1 | ULTRAVIOLET-STABILIZED CORROSION INHIBITORS | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2020-01-30 | — | — | US | disclosed |
| US-20190194189-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2019-06-27 | — | — | US | disclosed |
| US-20190036039-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2019-01-31 | — | — | US | disclosed |
| EP-3432381-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2019-01-23 | — | — | EP | disclosed |
| US-20140221379-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2014-08-07 | — | — | US | disclosed |
| US-8716303-B2 | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889901-B2 | Ultraviolet-stabilized corrosion inhibitors | TYR, UNG, MGMT | ELANE 1903/4885MAPT 1970/4885KMT2A 582/4885 |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | ELANE 4528/4885MAPT 3914/4885KMT2A 2160/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ELANE 3771/4885MAPT 4117/4885KMT2A 4267/4885 |
| US-20200032401-A1 | ULTRAVIOLET-STABILIZED CORROSION INHIBITORS | TYR, UNG, MGMT | ELANE 1903/4885MAPT 1970/4885KMT2A 582/4885 |
| US-10766893-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | PDE12, PDE3B, PDE5A | ELANE 3709/4885MAPT 300/4885KMT2A 2290/4885 |
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | ELANE 4095/4885MAPT 1413/4885KMT2A 641/4885 |
| US-20190036039-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, LEF1, CRY2 | ELANE 3385/4885MAPT 1129/4885KMT2A 351/4885 |
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | HTR5A, HTR2A, HTR1A | ELANE 2869/4885MAPT 425/4885KMT2A 2627/4885 |
| US-20190194189-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | PDE12, PDE3B, PDE5A | ELANE 3709/4885MAPT 300/4885KMT2A 2290/4885 |
| US-20140221379-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | ELANE 4528/4885MAPT 3914/4885KMT2A 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.